US EditionPublished • loading... • Updated
Pharmaceutical Grand Prix: Eli Lilly in the Lead, the Others in the Pits
Summary by Portfolio
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
A new era has begun in the pharmaceutical industry: investors are no longer simply looking for effective therapies, but for “consumer” medicines that are taken by the masses over the long term. As a result, stock market performances have diverged dramatically: while companies behind obesity and diabetes treatments are soaring, drugmakers operating in the traditional model are increasingly being pushed into the background on the stock market.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
